- Home
- ENLT vs ABVX Comparison
ENLT vs ABVX Comparison
Compare ENLT & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ENLT | ABVX |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | Israel | France |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 11.9B |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ENLT | ABVX |
|---|---|---|
| Price | $77.94 | $116.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 13 |
| Target Price | $48.83 | ★ $131.31 |
| AVG Volume (30 Days) | 130.1K | ★ 775.6K |
| Earning Date | 05-05-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $403.69 | $52.14 |
| Revenue Next Year | N/A | $4,132.27 |
| P/E Ratio | $76.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.03 | $69.81 |
| 52 Week High | $108.65 | $148.83 |
Technical Indicators
Market Signals| Indicator | ENLT | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 43.87 | 41.20 |
| Support Level | $65.61 | $107.67 |
| Resistance Level | $79.81 | $129.00 |
| Average True Range (ATR) | 1.90 | 3.35 |
| MACD | 0.00 | -0.14 |
| Stochastic Oscillator | 36.72 | 26.88 |
Price Performance
Historical ComparisonAbout ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, producing its revenue from the sale of the electricity which is produced through wind energy and solar energy in Europe.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.